Suzhou Ribo Life Science Co., Ltd. Stock Price

SEHK:6938 Community·HK$11.9b Market Cap

0 Narratives written by author
0 Comments on narratives written by author
0 Fair Values set on narratives written by author

Create a narrative

6938 Share Price Performance

HK$70.05

-12.05 (-14.68%)

HK$70.05

-12.05 (-14.68%)

HK$70.05

Mon, 16 Feb 26

Share Pricen/a

6938 Community Narratives

There are no narratives available yet.

Create a narrative

There are no community narratives available.

Trending Discussion

Snowflake Analysis

Adequate balance sheet with minimal risk.

1 Risk

1 Reward

View Full Analysis

Suzhou Ribo Life Science Co., Ltd. Key Details

Last Reported Earnings

Jun 30, 2025

Next Reporting Earnings

n/a

: -1.29
: 82.02%
: -122.54%
: 802.3%

View Full Analysis

About 6938

Founded: 2007
Employees: 404
CEO: Zicai Liang
WebsiteView website: www.ribolia.com

Suzhou Ribo Life Science Co., Ltd. researches and develops small nucleic acid drugs for treating cardiovascular, metabolic, renal, liver, and other diseases. It develops RBD4059 for treating thrombotic diseases; RBD5044 for treating hypertrigly ceridemia; RBD7022 for treating Hypercho lesterolemia; RBD1016 for treating CHB and CHD that are in Phase II clinical trials. The company also develops RBD7007 and RBD2080 for treating renal diseases; and RBD1119 for treating thrombotic diseases, which are in Phase I clinical trials. In addition, it develops SR122 for treating dyslipidemia; RBD3103 for treating renal diseases; and RBD8088 for treating glioma that are in preclinical trials. The company was founded in 2007 and is based in Kunshan, China.